Prognostic factors and molecular markers for renal cell carcinoma

Matthew H. Bui, Amnon Zisman, Allan J. Pantuck, Ken Ryu Han, Jeff Wieder, Arie S. Belldegrun*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review


Renal cell carcinoma is the most common cancer in the kidney, affecting nearly 30,000 Americans every year and is associated with over 12,000 deaths annually. If detected early, renal cell carcinomas can be cured surgically. However, once metastatic disease develops the prognosis for long-term survival is poor. Unfortunately, one-third of patients have metastatic disease at the time of diagnosis and approximately 50% of the patients undergoing surgical resection for less advanced disease eventually relapse. This review examines the clinical and molecular prognostic tools currently available or under investigation for kidney cancer.

Original languageEnglish
Pages (from-to)565-575
Number of pages11
JournalExpert Review of Anticancer Therapy
Issue number4
StatePublished - 2001
Externally publishedYes


  • Classification
  • Genetics
  • Kidney
  • Molecular markets
  • Prognostic factors
  • Renal cell
  • Staging


Dive into the research topics of 'Prognostic factors and molecular markers for renal cell carcinoma'. Together they form a unique fingerprint.

Cite this